Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2014-09-15, 12:31:02 | version 1.32.01
the association between exposure to common drugs such as aspirin and statins and the occurrence of cutaneous malignancies. Using the most advanced statistical methodology, previous observations of protective effects of these drugs on skin cancer incidence could not be confirmed. Using this pharmacy database, it was shown that psoriasis was not significantly associated with cardiovascular disease after adjusting for known confounders in Dutch patients from the general population.[8] In 2010, the department of dermatology actively engaged in ‘The Rotterdam Study’. Each of the approximately 15,000 participants of this population based cohort receive a total body skin examination.[9,10] The primary outcome of interest is the incidence of cutaneous (pre)malignancies, skin aging, varicose veins and inflammatory dermatoses in the general population. However, the richness of “The Rotterdam Study” enables us to investigate the many associations between these skin diseases and available characteristics, exposures and/or phenotypes. Most importantly we are now investigating in a large population based sample, the genetic epidemiology of skin cancer. References 1. Holterhues C, Vries E, Louwman MW, et al. Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol 2010; 130: 1807-12. 2. Flohil SC, Vries E de, Neumann HA, et al. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91: 24-30. 3. Flohil SC, Koljenovic´ S, Haas ER de, et al. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. Br J Dermatol 2011; 165: 874-81. 4. Joosse A, Collette S, Suciu S, et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol 2012; 30: 2240-7. 5. Joosse A, Koomen ER, Casparie MK, et al. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol 2009; 129: 2620-7. 6. Holterhues C, Hollestein LM, Nijsten T, et al. Burden of disease due to cutaneous melanoma has increased in the Netherlands since 1991. Br J Dermatol 2013; 169: 389-97. 7. Livingstone E, Hollestein LM, van Herk-Sukel MP, et al. ?-Blocker use and all-cause mortality of melanoma patients: Results from a population-based Dutch cohort study. Eur J Cancer. 2013; 49: 3863-71. doi:10.1016/j.ejca.2013.07.141 Epub 2013 Aug 10. 8. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-7. 9. Flohil SC, Leest R van der, Dowlatshahi E, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol 2013; 133: 1971-8. 10. Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study. J Invest Dermatol 2013; 133: 2347-54. 138 BWEADVSMGFINCORR:Opmaak 1 21-07-2014 17:40 Pagina 138